PEK fusion protein vaccineAlternative Names: PE-E7-K3
Latest Information Update: 25 May 2016
At a glance
- Originator Healthbanks Biotech Co
- Class Cancer vaccines; Protein-vaccines
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical intraepithelial neoplasia
Most Recent Events
- 14 Jun 2013 HealthBanks Biotech completes enrolment in its phase I trial for Cervical intraepithelial neoplasia in USA (NCT01880411)
- 13 Jun 2013 Phase-I for Cervical intraepithelial neoplasia in USA (Parenteral)